Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olutasidenib and Temozolomide in IDH1-Mutant High-Grade Glioma
NCT06161974Phase 2Recruiting
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Feb 2025
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of olutasidenib in glioma (3 arms), sponsored by Rigel Pharmaceuticals, Inc. Primary endpoints: Recommended Phase 2 Dose at 28 days, Progression-Free Survival at 24 months and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
olutasidenib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06161974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06161974.